Harvey N. Mayrovitz

Dr. Harvey N. Mayrovitz

orcid

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2009 in Lymphatic Research and Biology
Verified
Journal Article
Closed access
HMHarvey N. Mayrovitz
Harvey N. Mayrovitz
The standard of care for lymphedema encompasses risk reduction, early detection, Phase-I Complete Decongestive Therapy in a clinical setting, and Phase-II Self Management at home. This review discusses these lymphedema treatment components, including relevant physiological aspects that form the basis of treatment and an understanding of which are critical to successful outcomes. Phase-I therapy includes manual lymphatic drainage (MLD), short-stretch compression bandaging, decongestive exercise, skin care, and sometimes intermittent pneumatic compression (IPC). Home management includes many of the same elements, with adaptations for home treatment. Significant to the success of Phase-I and Phase-II care is effective bandaging and lymphatic drainage treatment via manual (MLD) or automated (IPC) processes. Truncal clearance plays a key role in facilitating lymphatic drainage from affected limbs by achieving effective pressure gradients, reducing lymphatic network resistance, and stimulating lymphatic contractility. The transition from Phase-I to Phase-2 presents challenges to patients and clinicians. Poor patient compliance with time-consuming technique dependent-home care regimens contribute to losing gains achieved in the clinic. Ineffective treatment results in complications, including increased pain, reduced range of motion and mobility, increased risk of infection, and other physical and psychological sequelae. The use of an advanced programmable IPC device for lymphedema treatment may support successful home management by addressing some of the home treatment barriers. Device selection requires careful consideration of the mode of action and device functionality. An advanced programmable device that provides truncal and proximal clearance and low applied pressure represents the current choice for such in-home devices.

1 December 1983 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
HMHarvey N. Mayrovitz
Harvey N. Mayrovitz
JRJ. Roy
J. Roy
The primary objectives of this study were 1) to determine the functional relationship between microvascular blood flow (Q) and arteriolar internal diameter (D) and 2) to determine whether this relationship conformed to a theoretical optimality prediction--that blood flow is proportional to the cube of the diameter (Q = kD3). Paired blood velocity and arteriolar diameter measurements in the cremaster muscle microvasculature of eight normotensive (WKY) and eight hypertensive (SHR) rats were made under control conditions and following maximal dilation of the microvasculature with topically applied adenosine. A total of 160 paired flow-diameter measurements were made in arteriolar vessels with diameters ranging from 6 to 108 micron. Analysis of this data showed that Q and D were functionally linked by Q = kDm with k = 417 and m = 3.01 with D expressed in centimeters. Confidence intervals at the 99.9% level were 331-503 and 2.86–3.14 for k and m, respectively. A theoretical development based on the minimization of the energy cost of blood volume and arteriolar wall volume led to a theoretical estimate for the range of k to be 92–132 and a value for m to be 3. Predicted pressure gradients in single vessels of the cat mesentery and shear rates in the rat cremaster based on Q = kD3 compared well with measured data reported in the literature and that determined in the present study. On the basis of the direct and predictive evidence, it is concluded that the relationship Q = kD3 represents a general average property of the microvasculature.

1 November 2001 in Advances in Skin & Wound Care
Verified
Journal Article
Closed access
HMHarvey N. Mayrovitz
Harvey N. Mayrovitz
NSNancy Sims
Nancy Sims
Pressure ulcers often occur at sites subjected to pressure and wetness. Although skin wetness is a risk factor for pressure ulcers, the mechanisms and effects of wetness versus urine constituents on skin breakdown is unclear. The hypothesis that wetness reduces skin hardness and, thereby, increases vulnerability of underlying blood vessels to pressure-induced flow reductions was tested in this study. Pads saturated with water and with a water solution mixed with the main chemical constituents of urine (synthetic urine; s-urine) were applied to forearm skin of 10 healthy subjects for 5.5 hours. Skin hardness, blood flow change caused by 60 mm Hg of pressure, erythema, and temperature were compared among dry, water, and s-urine test sites. 10 healthy women. Research Center, Nova Southeastern University, Health Professions Division, Fort Lauderdale, FL. S-urine and water caused significant reductions in initial hardness and caused greater initial perfusion decreases during pressure load when compared with dry sites. Skin temperature and erythema were lower at wet sites when compared with dry sites. The findings of this study are consistent with the concept that sustained skin wetness increases vulnerability to pressure-induced blood flow reduction. The effect appears to be mainly dependent on wetness, but urine constituents may exacerbate the effect. In addition, wetness-related skin cooling may play a role. In the healthy subjects studied, the blood flow decrease was not sustained due to perfusion recovery under pressure. Skin wetness would likely have more sustained effects in patients with compromised recovery mechanisms. Measures to diminish skin exposure to wetness in these patients, whatever the wetness source, are an important consideration in a multifaceted strategy to reduce the risk of pressure ulcers.

13 April 2023 in Cureus
Verified
Journal Article
Open access
PDF file
KSKyle J. Schulte
Kyle J. Schulte
HMHarvey N. Mayrovitz
Harvey N. Mayrovitz
Cardiovascular disease is the number one killer of females in the United States today, and myocardial infarction (MI) plays a role in many of these deaths. Females also present with more “atypical” symptoms than males and appear to have differences in pathophysiology underlying their MIs. Despite both differences in symptomology and pathophysiology being present in females versus males, a possible link between the two has not been studied extensively. In this systematic review, we analyzed studies examining differences in symptoms and pathophysiology of MI in females and males and evaluated possible links between the two. A search was performed for sex differences in MI in the databases PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature) Complete, Biomedical Reference Collection: Comprehensive, Jisc Library Hub Discover, and Web of Science. Seventy-four articles were ultimately included in this systematic review. Typical symptoms for both ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) such as chest, arm, or jaw pain were more common in both sexes, but females presented on average with more atypical symptoms such as nausea, vomiting, and shortness of breath. Females with MI also presented with more prodromal symptoms such as fatigue in days leading up to MI, had longer delays in presentation to the hospital after symptom onset, and were older with more comorbidities than males. Males on the other hand were more likely to have a silent or unrecognized MI, which concurs with their overall higher rate of MI. As they age, females have a decrease in antioxidative metabolites and worsened cardiac autonomic function than male. In addition, at all ages, females have less atherosclerotic burden than mles, have higher rates of MI not related to plaque rupture or erosion, and have increased microvasculature resistance when they have an MI. It has been proposed that this physiological difference is etiologic for the male-female difference in symptoms, but this has not been studied directly and is a promising area of future research. It is also possible that differences in pain tolerance between males and females may play a role in differing symptom recognition, but this has only been studied one time where females with higher pain thresholds were more likely to have unrecognized MI. Again, this is a promising area for future study for the early detection of MI. Finally, differences in symptoms for patients with different atherosclerotic burden and for patients with MI due to a cause other than plaque rupture or erosion has not been studied and are both promising avenues to improve detection and patient care in the future.

2 May 2012 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
CFCaroline E. Fife
Caroline E. Fife
SDSuzanne Davey
Suzanne Davey
EMErik A. Maus
Erik A. Maus
RGRenie Guilliod
Renie Guilliod
HMHarvey N. Mayrovitz
Harvey N. Mayrovitz
Purpose Pneumatic compression devices (PCDs) are used in the home setting as adjunctive treatment for lymphedema after acute treatment in a clinical setting. PCDs range in complexity from simple to technologically advanced. The objective of this prospective, randomized study was to determine whether an advanced PCD (APCD) provides better outcomes as measured by arm edema and tissue water reductions compared to a standard PCD (SPCD) in patients with arm lymphedema after breast cancer treatment. Methods Subjects were randomized to an APCD (Flexitouch system, HCPCS E0652) or SPCD (Bio Compression 2004, HCPCS E0651) used for home treatment 1 h/day for 12 weeks. Pressure settings were 30 mmHg for the SPCD and upper extremity treatment program (UE01) with standard pressure for the APCD. Thirty-six subjects (18 per group) with unilateral upper extremity lymphedema with at least 5% arm edema volume at the time of enrollment, completed treatments over the 12-week period. Arm volumes were determined from arm girth measurements and suitable model calculations, and tissue water was determined based on measurements of the arm tissue dielectric constant (TDC). Results The APCD-treated group experienced an average of 29% reduction in edema compared to a 16% increase in the SPCD group. Mean changes in TDC values were a 5.8% reduction for the APCD group and a 1.9% increase for the SPCD group. Conclusion This study suggests that for the home maintenance phase of treatment of arm lymphedema secondary to breast cancer therapy, the adjuvant treatment with an APCD provides better outcomes than with a SPCD.